Co-encapsulation of live cells with oxygen-generating particles

Patent metadata

Field	Value
Publication number	US-9775866-B2
Application number	US-201715411351-A
Country	US
Kind code	B2
Filing date	Jan 20, 2017
Priority date	Aug 9, 2011
Publication date	Oct 3, 2017
Grant date	Oct 3, 2017

Abstract

Microcapsules are described that comprise (a) a liquid aqueous or hydrogel core; (b) a semipermeable membrane surrounding said core; (c) live animal cells (e.g., pancreatic cells) in the core; and (d) oxygen-generating particles in said core, said oxygen-generating particles included in said microcapsules in an amount sufficient to lengthen the duration of viability of said animal cells in said microcapsules. Compositions comprising such microcapsules and uses thereof, such as in treating diabetes, are also described.

First claim

That which is claimed is:

1. A microcapsule comprising:
(a) a liquid aqueous or hydro gel core;
(b) a semipermeable membrane surrounding said core;
(c) live animal cells in said core, wherein said live animal cells are myocytes or pancreatic islet cells; and
(d) oxygen-generating particles in said core, said oxygen-generating particles included in said microcapsules in an amount sufficient to lengthen the duration of viability of said animal cells in said microcapsules,
wherein said oxygen-generating particles comprise an inorganic peroxide selected from the group consisting of calcium peroxide, magnesium peroxide, sodium peroxide, sodium percarbonate, benzylperoxide, and combinations thereof, and
wherein said microcapsule further comprises catalase or a metalloporphyrin antioxidant.

2. The microcapsule of claim 1 , wherein said oxygen-generating particles further comprise a radical trap or peroxide decomposition catalyst.

3. The microcapsule of claim 1 , said microcapsule further comprising an auxiliary layer surrounding said semipermeable layer.

4. The microcapsule of claim 3 , wherein said auxiliary layer comprises a biodegradable polymer, said biodegradable polymer optionally containing an active compound.

5. The microcapsule of claim 4 , wherein said auxiliary layer contains a pro-angiogenic agent in an amount effective to enhance the growth of blood vessels adjacent said microcapsule.

6. The microcapsule of claim 1 , wherein said animal cells are mammalian cells.

7. The microcapsule of claim 6 , wherein said mammalian cells are myocytes.

8. The microcapsule of claim 1 , wherein said cells are pancreatic islet cells.

9. A composition comprising a plurality of microcapsules of claim 1 .

10. The composition of claim 9 , further comprising a pharmaceutically acceptable carrier.

11. A method of treating diabetes in a subject in need thereof, comprising implanting microcapsules of claim 8 in said subject in a treatment-effective amount, wherein said microcapsules comprise pancreatic islet cells.

12. The microcapsule of claim 1 , wherein said inorganic peroxide is calcium peroxide.

13. The microcapsule of claim 1 , wherein said oxygen-generating particles comprise catalase.

14. The microcapsule of claim 1 , wherein said cells are myocytes.

Assignees

• Univ Wake Forest Health Sciences

Inventors

• Opara Emmanuel C
• Harrison Benjamin S

Classifications

• C12N11/04

  entrapped within the carrier, e.g. gel or hollow fibres · CPC title

• A61K31/555

  containing heavy metals, e.g. hemin, hematin, melarsoprol · CPC title

• A61K9/5073

  having two or more different coatings optionally including drug-containing subcoatings · CPC title

• A61K47/42

  Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title